论文部分内容阅读
目的探讨性激素和促性腺激素对前列腺癌的影响。方法对1996-01-01—2005-12-31解放军总医院内分泌科测定53例确诊未治的前列腺癌患者性激素:睾酮(T)、雌二醇(E2)与促性腺激素,包括黄体生成素(LH)、卵泡刺激素(FSH),同时测定了253名正常对照者的性激素与促性腺激素。结果前列腺癌组总睾酮和反映游离睾酮的指标睾酮分泌指数(TSI)以及FSH均低于正常对照组,且均有统计学意义(P<0·05)。E2、LH两组比较无统计学意义(P>0·05)。结论(1)前列腺癌患者处于低雄激素水平。(2)当睾酮(正常为15nmol/L)或睾酮分泌指数(正常为4·0)低于诊断标准时,前列腺癌的发病率可能升高。
Objective To investigate the effects of sex hormones and gonadotropins on prostate cancer. Methods The endocrine department of PLA General Hospital from January 1996 to January 31, 2005 was used to determine the levels of sex hormones in testosterone (T), estradiol (E2) and gonadotrophin in 53 patients with confirmed prostate cancer, including luteinizing hormone (LH) and follicle stimulating hormone (FSH) were measured. The sex hormones and gonadotrophin in 253 normal controls were also determined. Results The total testosterone and testosterone secretion index (TSI) and FSH, which reflect free testosterone, in prostate cancer group were lower than those in normal control group (P <0.05). There was no significant difference between E2 and LH groups (P> 0.05). Conclusions (1) Patients with prostate cancer are at low androgen levels. (2) The incidence of prostate cancer may increase when testosterone (15 nmol / L normal) or testosterone secretion index (normal 4.0) falls below the diagnostic criteria.